Overview
- The phase 1 results were published on Thursday, July 16, 2026, reporting first‑in‑human testing of mKRAS‑VAX in 20 people with inherited risk and pancreatic abnormalities.
- Eighteen of 20 participants, or 90 percent, mounted a mutation‑specific T‑cell response with a median 18.2‑fold increase and vaccine‑induced T‑cell clones detectable up to two years.
- The vaccine was well tolerated with only mild to moderate side effects such as injection‑site reactions, fatigue, chills and flu‑like symptoms that resolved without treatment.
- After a median 16.5 months of follow‑up none of the participants developed pancreatic cancer or high‑risk lesions needing surgery, and an exploratory scan review found five complete cyst resolutions and three partial regressions.
- Researchers have opened a study to examine vaccine effects in resected high‑risk pancreatic tissue, and the team disclosed licensing and equity ties to Adventris Pharmaceuticals while stressing that prevention efficacy is unproven and requires larger trials.